Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
March 26, 2024 12:45 ET
|
F. Hoffmann-La Roche Ltd
The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malariaMalaria is a serious and potentially fatal parasitic infection most commonly transmitted by...
Roche Generalversammlung 2024
March 12, 2024 08:30 ET
|
F. Hoffmann-La Roche Ltd
Alle Anträge des Verwaltungsrates genehmigtSeverin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und Verwaltungsräte bestätigt 37....
Assemblée générale 2024 de Roche
March 12, 2024 08:30 ET
|
F. Hoffmann-La Roche Ltd
Adoption de toutes les propositions du Conseil d’administrationRéélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les autres membres du Conseil...
Roche Annual General Meeting 2024
March 12, 2024 08:30 ET
|
F. Hoffmann-La Roche Ltd
All proposals of the Board of Directors approvedSeverin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election confirmed37th consecutive dividend...
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
March 05, 2024 07:30 ET
|
F. Hoffmann-La Roche Ltd
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month three Zilebesiran added to a standard of care...
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
February 25, 2024 14:00 ET
|
F. Hoffmann-La Roche Ltd
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed...
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
February 16, 2024 11:24 ET
|
F. Hoffmann-La Roche Ltd
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate...
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
February 01, 2024 01:03 ET
|
F. Hoffmann-La Roche Ltd
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months...
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft Guidance für 2023 und erzielt trotz stark rückläufigem COVID-19-Umsatz Verkaufswachstum von 1% (CER)
February 01, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Konzernverkäufe steigen um 1%1 zu konstanten Wechselkursen (CER; -7% in CHF) und gleichen damit Umsatzrückgang bei COVID-19-Produkten und Erosion durch Biosimilars mehr als aus; Guidance für 2023 wird...
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
February 01, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Group sales grow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding...